 InfuSystem is uniquely positioned to benefit from any resurgence in COVID-19, and ex-COVID has strength in the core business model. Shareholders have enjoyed 120 upside YTD, and shares have the legs to deliver more on the back of INFUs strong sequential performance YTD. 